Rate of β-amyloid accumulation varies with baseline amyloid burden: Implications for anti-amyloid drug trials

Guo, Tengfei; Dukart, Juergen; Brendel, Matthias; Rominger, Axel Oliver; Grimmer, Timo; Yakushev, Igor (2018). Rate of β-amyloid accumulation varies with baseline amyloid burden: Implications for anti-amyloid drug trials. Alzheimer's & dementia, 14(11), pp. 1387-1396. Elsevier 10.1016/j.jalz.2018.05.013

[img] Text
Guo_2018_A_D.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

INTRODUCTION: This study examined a longitudinal trajectory of β-amyloid (Aβ) accumulation at the predementia stage of Alzheimer's disease in the context of clinical trials. METHODS: Analyzed were baseline (BL) and 2 years' follow-up 18F-florbetapir positron emission tomography data of 246 Aβ-positive subjects with normal cognition and mild cognitive impairment. We studied the relationship between annual accumulation rates of 18F-florbetapir and BL standard uptake value ratios in whole gray matter (SUVRGM). RESULTS: Subjects with BL SUVRGM of 0.56 to 0.92 (n = 134) appeared to accumulate Aβ approximately 1.5 times faster than remaining subjects. In subjects with SUVRGM above 0.95, most regions with the highest annual accumulation rate were outside the established set of Alzheimer's disease typical regions. CONCLUSION: There are global and regional variations in annual accumulation rate at the predementia stage of Alzheimer's disease. When taken into account, the sample size in anti-amyloid trials can be substantially reduced. Critically, treated and placebo groups should be matched for BL SUVRGM.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Clinic of Nuclear Medicine

UniBE Contributor:

Rominger, Axel Oliver

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1552-5279

Publisher:

Elsevier

Language:

English

Submitter:

Sabine Brand

Date Deposited:

10 Apr 2019 11:56

Last Modified:

10 Apr 2019 11:56

Publisher DOI:

10.1016/j.jalz.2018.05.013

PubMed ID:

30420035

Uncontrolled Keywords:

Alzheimer's disease; Amyloid imaging; Anti-amyloid; Clinical trial; Florbetapir; Mild cognitive impairment; Positron emission tomography

BORIS DOI:

10.7892/boris.125646

URI:

https://boris.unibe.ch/id/eprint/125646

Actions (login required)

Edit item Edit item
Provide Feedback